Latest MS research news

Latest MS research news | 02 July 2013

Progression in disability and regional grey matter atrophy in relapsing-remitting MS

In this study researchers found regional grey matter volume reductions occurred in the right parietal lobe, showing significant loss of apparent cortical grey matter thickness over one year in precuneus and postcentral areas in those with progressive disability, compared to stable disability.

From MSIF

Latest MS research news | 02 July 2013

Sodium accumulation is associated with disability and a progressive course in MS

This study demonstrates increased sodium within MS lesions, normal appearing white matter, cortical and deep grey matter in MS, with higher concentrations seen in secondary-progressive MS and in people with greater disability. The increased sodium may reflect neuroaxonal dysfunction which leads to clinical progression and increased disability.

From MSIF

Latest MS research news | 02 July 2013

Neuropsychological rehabilitation does not improve cognitive performance but reduces perceived cognitive deficits in patients with MS

This study found that short-term neuropsychololgical rehabilitation does not seem to improve cognitive performance but it reduces the perceived cognitive deficits in people with MS.

From MSIF

Latest MS research news | 24 June 2013

Differential microRNA expression in blood in MS

This study group investigated the expression of microRNAs (miRNAs) in peripheral blood mononuclear cells and miRNAs in plasma and serum samples. They found three differentially expressed miRNAs to be significantly induced in MS and one of these members correlated with expression of the proinflammatory cytokine IL1B.

From MSIF

Latest MS research news | 24 June 2013

Genetic risk variants in African Americans with MS

This is the largest genetic study of an MS data-set of non-European ancestry. They replicated established HLA-DRB1 allelic associations. They also confirmed the protective role association of HLA-A*02:01

From MSIF

Latest MS research news | 24 June 2013

Siponimod for patients with relapsing-remitting MS: an adaptive, dose-ranging, randomised, phase 2 study

Siponimod acts in a similar way to fingolimod but is more selective in the receptors which it targets, with a theoretically improved efficacy and safety profile. This phase 2 trial demonstrated therapeutic effects of siponimod on MRI lesion activity and was quite well tolerated in people with relapsing-remitting MS.

From MSIF

Latest MS research news | 18 June 2013

Tobacco smoking and disability progression in MS: UK cohort study

This study demonstrated that regular smoking is associated with more severe disease as well as faster progression of disability. Stopping smoking either before or after the onset of MS is associated with slower progression of disability.

From MSIF

Latest MS research news | 18 June 2013

Confounding underlies the apparent month of birth effect in MS

Several groups have previously reported the apparent seasonal patterns for month of birth suggested to be specific to MS, that is to say increased in those born in spring and reduced in the winter. The analysis carried out by this study group indicates that the apparent seasonal patterns for month of birth are expected by chance alone and so are probably false positives.

From MSIF

Latest MS research news | 18 June 2013

Magnetic resonance frequency shifts during acute MS lesion formation

The researchers looked at a new imaging technique on the MRI scanner which detects an increase in frequency shifts of the MR signal. They found that the increase in MR frequency was seen one month before and one month after contrast enhanced lesions appeared on conventional MRI.

From MSIF

Latest MS research news | 10 June 2013

Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome

This study demonstrates the potential use of a specific biomarker in the cerebrospinal fluid which may be of use in the future to help in the diagnostic process of MS.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial